innovation sources of domestic and foreign companies with rich experience in new drug development, including: academic research, small biotechnology companies, and international pharmaceutical companies, for joint research and development, technology introduction, etc. In a way that closely combines the energy of both parties to develop drug development, and then introduces the most suitable CRO and CMO strategic partners to promote innovative drugs to the “proof of concept” (POC) stage, followed by authorization and partnering. In this way, the research and development of innovative drugs will be handed over to the most potential development team, and the late clinical trials of drug research and development will be carried out to push the products to the market.